Dr. Siegall is the founder and the Chief Executive Officer of Seattle Genetics. The firm was founded in 1998 and specializes in biotechnology particularly the innovation, development, and improvement of therapy-drugs. The company developed the first Food and Drug Administration (FDA) – approved antibody-drug conjugate, which led to the development of over twenty drugs. Also, it attracted other organizations with a desire for a partnership like the Pfizer, Genentech among others.
The company can now stand to be counted as an authority in the area of cancer research thanks to the leadership of Dr. Siegall. Its future is even brighter with more plans being laid to expand the company’s drug holdings. Additionally, the company aspires to offer more endurable and potent drugs that will take the place of the old-type of cancer treatment like the systematic chemotherapy, efficiently restoring hope to those who otherwise consigned to death, extensive surgery, and amputation.
Seattle Genetics also has a vibrant and talented team of sales staff, with knowledge of biotech and consequently the product and the overall business generating huge sales returns, more so, the drug is fashioned to sell itself in that, it’s unique. The business deals executed are tremendous and worth the time, energy and revenue put into it.
Clay Siegall graduated from the Maryland University with a bachelor of science, Zoology and later graduated from George Washington with a Ph.D. in Genetics. Siegall was always interested in medicine and how one can use technology to intervene the path of creation and even revive health and this influence his choice of Zoology. His interest in Cancer treatment grew from his encounter with a family member diagnosed with cancer. The journey through the therapy left him convinced that more could be done to improve the situation.
Before founding the Seattle Genetics, Dr. Siegall worked at a Pharmaceutical Research Institute, the Bristol-Myers Squibb, and the National Institute of health and the National Cancer Institute. He has also operated in private biotech companies such as the Alder Biopharmaceuticals, as a board of directors. He is also a distinguished author of over seventy publications.